AI Detects Hidden Pancreatic Cancer Early Plus Key IBD and Liver Findings
A roundup of gastroenterology research covers AI cancer detection, IBD drug safety, GLP-1 combos for liver disease, and more.
Summary
A MedPage Today gastroenterology roundup highlights several findings relevant to long-term health. An AI model successfully detected pancreatic cancer before it became visually apparent on imaging — a major step for early intervention. IBD patients on JAK inhibitors faced the highest infection risk, while ustekinumab showed the lowest. GLP-1 agonists combined with SGLT2 inhibitors outperformed either drug alone in reducing liver and cardiovascular events in type 2 diabetes patients with fatty liver disease. Physical activity was linked to lower IBS risk in a large real-world study. These findings span cancer screening, autoimmune disease management, metabolic health, and gut function — all directly relevant to healthspan and disease prevention.
Detailed Summary
This MedPage Today roundup covers a broad sweep of gastroenterology and hepatology research published in late April 2026, touching on several topics with direct longevity and healthspan implications.
The most striking finding comes from an AI model published in Gut that detected pancreatic cancer at its visually occult pre-diagnostic stage — meaning before standard imaging could identify it. Pancreatic cancer is notoriously deadly partly because it is rarely caught early. AI-assisted early detection could meaningfully shift survival outcomes for one of medicine's hardest-to-treat cancers.
For the estimated 3 million Americans with inflammatory bowel disease, drug safety data matters enormously. A Medicare-based study found no elevated cardiovascular risk from immunomodulators or biologics compared to 5-aminosalicylic acid. However, JAK inhibitors carried the highest serious infection risk among advanced IBD therapies, while ustekinumab showed the lowest — a clinically important distinction for patients and prescribers weighing treatment options.
In metabolic health, patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease who took both a GLP-1 agonist and an SGLT2 inhibitor had significantly lower risks for major liver and cardiovascular events than those on either drug alone. This combination therapy signal, published in Hepatology, reinforces the growing case for multi-drug metabolic strategies in high-risk patients.
Physical activity was associated with a lower likelihood of irritable bowel syndrome in a large real-world study, adding gut health to the already extensive list of exercise benefits. Globally, hepatitis B and C caused 1.3 million deaths in 2024, underscoring that infectious liver disease remains a major preventable mortality burden. Caveats apply throughout: several studies were retrospective or small, and findings should be confirmed in prospective trials before changing clinical practice.
Key Findings
- AI model detected pancreatic cancer before it was visible on standard imaging, enabling earlier intervention
- JAK inhibitors carried highest serious infection risk in IBD; ustekinumab had the lowest risk
- Combining GLP-1 agonist and SGLT2 inhibitor reduced liver and cardiovascular events more than either drug alone
- Greater physical activity linked to lower IBS likelihood in a large real-world population study
- Hepatitis B and C caused 1.3 million global deaths in 2024, with 2030 elimination targets at risk
Methodology
This is a curated news roundup by MedPage Today summarizing multiple peer-reviewed studies published in journals including Gut, JAMA Network Open, Hepatology, and Clinical Gastroenterology and Hepatology. Source credibility is high given the journal pedigree, though the roundup format provides limited methodological detail. Evidence ranges from large real-world studies to small randomized trials and retrospective analyses.
Study Limitations
The roundup format lacks granular study details such as sample sizes, follow-up duration, and effect sizes for most findings. Several cited studies are retrospective, limiting causal inference. Readers should consult primary sources in Gut, Hepatology, and JAMA Network Open for full methodology before drawing clinical conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.